Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (351-360 of 499) with videos related to

Pageof 50
Sort By:
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
Lancet (London, England)|November 27, 2012
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialAxel Grothey, Eric Van Cutsem, Alberto Sobrero, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2022
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 yearsDemetris Papamichael, Guilherme S Lopes, Curt L Olswold, et al.
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.
The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Molecular Cancer Therapeutics|July 19, 2017
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction CancerJosep Tabernero, Atsushi Ohtsu, Kei Muro, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.
Pageof 50

Showing results (351-360 of 499) with videos related to

Sort By:
Pageof 50
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
Lancet (London, England)|November 27, 2012
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialAxel Grothey, Eric Van Cutsem, Alberto Sobrero, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2022
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 yearsDemetris Papamichael, Guilherme S Lopes, Curt L Olswold, et al.
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.
The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Molecular Cancer Therapeutics|July 19, 2017
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction CancerJosep Tabernero, Atsushi Ohtsu, Kei Muro, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.
Pageof 50